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Abstract
Background: Extracorporeal shock wave lithotripsy (ESWL) is an effective therapeutic method used to treat patients
with pancreatic stones. However, the anesthesia for this procedure has been underappreciated, with minimal reports of
these procedures in certain case series with general or epidural anesthesia.
Methods: A cohort of 60 patients who elected to undergo ESWL in order to treat pancreatic stones for the first time
were randomly selected and divided into two groups. One group of patients received target controlled infusion (TCI)
of remifentanil, while the other group of patients received TCI of remifentanil plus a bolus of flurbiprofen axetil
(a cyclooxygenase inhibitor) (Rem group and Rem + Flu group, n = 30 for each group). The Dixon’s up-and-down
method was used to calculate the half maximum effective concentration (EC50) of remifentanil. Visual analogue
scales of pain, Ramsay sedation scale, hemodynamic changes, and adverse events were also recorded.
Results: The EC50 of remifentanil was calculated to be 4.0 ng/ml (95 % confidential interval: 3.84 ng/ml, 4.16 ng/ml)
and 2.76 ng/ml (95 % confidential interval: 2.63 ng/ml, 2.89 ng/ml) in the Rem group and Rem+ Flu group respectively
(p < 0.001). Pain score was comparable between the two groups, while the Ramsay sedation scale was higher in the
Rem group. Hemodynamic data showed that patients in the Rem group experienced higher mean arterial pressures
and higher heart rates across the procedures. Patients in Rem group demonstrated a lower respiratory rate (p < 0.001)
and a lower SpO2 (p = 0.001). Less adverse events occurred in Rem+ Flu group, including a reduced respiratory
depression requiring wake-up as well as reduced postoperative nausea and vomiting.
Conclusion: Remifentanil plus flurbiprofen axetil provided satisfactory analgesia and sedation for ESWL of pancreatic
stones with less adverse events. (Clinicaltrial.gov: NCT01998217; registered on November 19, 2013)
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Background
Intracanalar or intraductal stones are pathognomonic
symptoms of chronic pancreatitis, where these stones
tend to cause further obstruction of outflow from the
pancreas, ultimately leading to recurrent attacks of pan-
creatitis and abdominal pain [1, 2]. Extracorporeal shock
wave lithotripsy (ESWL) has been used over the past
two decades to help treat pancreatic stones, when
routine endotherapy cannot be effectively applied [3, 4].
Despite providing pain relief to these patients through
ESWL,, the procedure itself is quite painful and requires
the addition of anesthesia in a patient’s treatment plan
[5]. Moreover, general anesthesia or epidural anesthesia
has been utilized for this procedure [5–8], but the
elucidation of its effectiveness has infrequently been
documented. General anesthesia and epidural anesthesia
are known to be invasive procedures due to the involve-
ment of tracheal intubation or epidural puncturing. Both
of these processes are time-consuming and require long
induction and/or recovery periods.
Monitored anesthesia care with propofol and/or opioids
has been clinically applied in the conduction of ESWL of
stones in the urinary system, yielding a satisfactory sed-
ation and analgesia results, which is complimented with a
shorter recovery time as well [9]. In addition to this, single
use of opioids such as remifentanil, fentanyl and sufentanil
has also been proposed as an ideal sedation strategy for
ESWL of kidney stones [10, 11]. Remifentanil seems to be
a more suitable remedy on the grounds that it harbors a
lower rate of incidence in events related to respiratory
depression and postoperative nausea and vomiting
(PONV) [11]. However, there has been a dismal amount
of published literature reports describing the quantity at
which remifentanil can be considered an effective and safe
therapy for ESWL of pancreatic stones. In this study, we
sought to report the single use of remifentanil, which was
administered through target-controlled infusion (TCI),
both in the presence and absence of a cyclooxygenase in-
hibitor, flurbiprofen axetil, in ESWL of pancreatic stones.
Methods
Study design
This was a prospective, open-label, randomized con-
trolled clinical trial. This study was approved by the
Committee on Ethics of Biomedicine Research, Second
Military Medical University, Shanghai, China. Informed
consent was obtained from all patients or a surrogate
individual before recruitment into the study.
Patient inclusion and randomization
The sixty patients enrolled in this study were diagnosed
with chronic pancreatitis for the first time, and were
treated with ESWL for pain relief in the Center of
Gastrointestinal Endoscopy, Changhai Hospital. Patients
were enrolled and recruited continuously from September
2012 to December 2013. The patients were randomly
allocated into one of two groups, based on an assigned
number that was randomly generated on a computer
before assignment to the patient. Both groups, Rem group
and Rem + Flu group, consisted of thirty individual
members (n = 30). Randomization was performed by JFW
and enrollment of the patients was conducted by YGY
and LHH.
The inclusion criteria for ESWL indication were met
based on previous reports [12, 13]. Patients undergoing
ESWL were excluded from this study, if the following
criteria were met: 1) aged ≤18 years or ≥ 65 years; 2)
ASA III or higher; 3) patients with hypertension; 4)
patients with compromised cardiopulmonary function;
5) patients that have undergone ESWL. Patients would
also be excluded in the presence of life-threatening ad-
verse events such as cardiovascular or respiratory failure,
as well as mechanical complications induced by the
ESWL procedure.
Trial protocol
After recruitment, patients were instructed to describe
their pain based on the use of the visual analogue scale
(VAS) (0: no pain; 10: worst possible pain). Electrocardio-
gram (ECG), heart rate (HR), non-invasive blood pressure
(BP), pulse oximetry (SpO2) and respiratory rate (RR) were
all monitored through the use of the M1106C multi-
function monitor (HP, Palo Alto, USA). For sedation
induction, 2 L/min of oxygen was inspired and target-
controlled infusion of remifentanil (Renfu Pharmaceutical
Co., Ltd., Yichang, China) was initiated at the predeter-
mined effect-site by using the Minto model in a Fresenius
Vial computer-assisted syringe pump (Fresenius Vial,
Grenoble, France). Fluobiprofen axetil (50 mg, Tide
Pharmaceutical Co. Ltd., Beijing, China) was administered
before the infusion of remifentanil in the Rem + Flur
group. ESWL (Compact Delta II, Dornier Med Tech.,
Wessling, Germany) was initiated 3 min after the effect-
site concentration reached a relatively stable level. Shock
waves up to a maximum of 5000 shocks were delivered
per sitting. An intensity of 6 (16,000 kV) on a scale of 1 to
6 was used with a frequency of 120 shocks/min during the
procedure.
The initial concentration of remifentanil was set at
3 ng/ml, and 0.5 ng/ml was chosen as the ideal concen-
tration step for either increment or decrement accord-
ing to the Dixon’s up-and-down method [14]. A
positive response was defined as a VAS score higher
than 3 or a complaint of insufferable pain by the pa-
tient. In either case, the analgesic effect was considered
to be inadequate, and the concentration of remifentanil
in the next patient would be increased by 0.5 ng/ml.
For the patients that experienced insufferable pain, the
Yang et al. BMC Anesthesiology  (2015) 15:161 Page 2 of 7
concentration of remifentanil was appropriately titrated
to a specific level that corresponded to a VAS score
lower than 3 to offset insufferable pain. A negative
response was defined as one that contained a VAS score
that was lower than 3. The concentration of remifenta-
nil in the next set of patients for this case would be de-
creased by a concentration of 0.5 ng/ml. If the patients
were over-sedated, an indication that was detected by a
SpO2 lower than 91 % or a respiratory rate lower than
ten times per minute, then the patients were woken up
and were requested to take deep breathes. Ventilation
with the facial mask would be initiated, if the patients
did not awake or if they could not maintain spontan-
eous breathing patterns. If an increase in remifentanil
was unable to alleviate the unbearable pain associated
with the procedure, the patient would be given the
opportunity to request for general anesthesia. Remifen-
tanil infusion was terminated after the completion of
ESWL, and the patients were transferred to a recovery
room and were medically monitored for an additional
30 min.
Data collection and outcome
Physical signs included: HR, SpO2, mean arterial pressure
(MAP), and RR, all of which were recorded before induc-
tion, after induction, and every 5 min after initiation of
ESWL, by HC and JBL, who were blinded to the grouping.
VAS score and Ramsay sedation scale (0, does not respond
to test stimulus; 1, does not respond mild prodding or
shaking; 2, responds only after mild prodding or shaking;
3, responds only after name is called loudly and/or repeat-
edly; 4, lethargic response to name spoken in normal tone;
5, responds readily to name spoken in a normal tone; 6,
agitated) were also assessed every 5 min.
The primary outcome is the half maximal effective
concentration (EC50) of remifentanil in the two groups.
The secondary outcome included VAS score, Ramsay
sedation scale, as well as hemodynamic and respiratory
parameters. The incidences of adverse effects recorded
were: respiratory repression requiring waking up, chest
wall rigidity, pruritus, and PONV within the first 24 h
after procedure.
Sample size
The calculation of the sample size for an up-and-down
method has not been clearly defined, but a sample size
of 20 – 40 for each group is generally considered accept-
able [15]. Therefore, a total of 30 patients were included
for each group in this study.
Statistical analysis
All statistical processes were accomplished in SPSS
16.0. The continuous data in normal distribution were
expressed as mean ± standard derivation (SD) and those
in non-normal distribution were expressed as mean
(25 % percentile, 75 % percentile). The EC50 of remifen-
tanil was calculated by the isotonic regression estima-
tors, which were proposed in a report by Pace et al.
When an order violation was present, the pooled
adjacent-violator algorithm was used for adjustment
[15–17]. Comparison of the concentrations was accom-
plished by student’s t test following the logarithm trans-
formation. VAS score and Ramsay sedation scale were
compared by the Mann–Whitney test. The HR, BP, RR
and SpO2 were compared in relation to the baseline
level by using Student’s t-test. Chi-square test was used
to compare the incidences of side effects. A p < 0.05
was considered to be statistically significant.
Results
All 60 patients completed the study, and no patient
ceased participation during the study for safety issues.
The patients included in this study were all eligible for
data analysis (Fig. 1). The demographic data of the pa-
tients are described in Table 1. The age, gender, height,
weight, body mass index and procedure duration were
similar amongst the two groups.
The hemodynamic changes of the individuals in re-
sponse to the ESWL procedures are shown in Fig. 2. A
negative response led to a 0.5 down-regulation of the
remifentanil concentration and vice versa. EC50 was
calculated by the isotomic regression estimators with
adjustment of pooled adjacent-violator algorithm, in
both groups. The EC50 was 4.0 ng/ml (95 % confidential
interval: 3.84 ng/ml, 4.16 ng/ml) and 2.76 ng/ml (95 %
confidential interval: 2.63 ng/ml, 2.89 ng/ml) in Rem
group and Rem + Flu group respectively. The Student’s
t test after the logarithm transformation showed that
Fig. 1 Flow diagram of the recruitment process
Yang et al. BMC Anesthesiology  (2015) 15:161 Page 3 of 7
the remifentanil concentration was significantly lower
in Rem + Flu group in comparison to the Rem group
(p < 0.001).
The median VAS scores were 3.0 (1.0, 5.0) and 4.0 (2.0,
5.3) in the Rem group and Rem+ Flu group (p = 0.353).
But the Ramsay sedation scale in Rem group was signifi-
cantly higher [3.0, (2.0, 4.0)] than that in the Rem+ Flu
group [3.0, (2.0, 3.0)] (p = 0.032) (Fig. 3). The hemodynamic
data showed that patients in Rem group had higher MAP
and HR than the patients in the Rem+ Flu group, at both
the highest level and after procedure (p < 0.05) (Fig. 4).
The lowest SpO2 in the Rem group is 97.3 ± 0.24 %,
slightly lower than the 98.3 ± 0.17 % in Rem + Flu group
(p = 0.001). The RRs at both the lowest and highest
levels were significantly lower in Rem group than in the
Rem + Flu group (p < 0.001) (Fig. 5).
No severe adverse events occurred during the study.
Furthermore, no participants were subjected to assisted
ventilation or general anesthesia due to over-sedation
and insufficient analgesia. The most common adverse
event recorded was PONV, followed by pruritus, and then
by respiratory repression requiring waking up. However,
incidences of respiratory repression requiring waking up
and PONV were significantly lower in the Rem + Flu
group than in the Rem group (p < 0.05) (Table 2).
Discussion
This study establishes a novel safe and effective sedation
strategy for ESWL of pancreatic stones with remifenta-
nil, in the presence and absence of flurbiprofen axetil.
The addition of flurbiprofen axetil was observed to sig-
nificantly decrease the requirement of remifentanil,
while simultaneously promoting a reduction in the side
effects of remifentanil, such as respiratory depression
and PONV.
ESWL technique has been previously used in treating
pancreatic stones over the past three decades, providing
satisfactory pain relief for patients and less demand for
surgery. Although general anesthesia and epidural
anesthesia has been well accepted in certain centers [5–8],
few studies have been performed to investigate the
suitability of anesthetic technique for pancreatic ESWL.
Our present study suggests that a single infusion of remi-
fentanil is an ample amount for analgesia and sedation
during ESWL. Furthermore, this single infusion prevented
tracheal intubation and epidural puncture. The sedation
strategy with remifentanil reduced the induction and re-
covery time of conventional general or epidural anesthesia,
Table 1 Demographic data of the participants
Rem (n = 30) Rem + Flu (n = 30) P value
Age 42.2 ± 11.3 40.7 ± 8.3 0.552
Gender 22/8 19/11 0.405
Height 169.2 ± 7.1 166.3 ± 8.2 0.154
Weight 57.8 ± 8.4 58.3 ± 10.6 0.844
BMI 20.2 ± 2.5 20.9 ± 2.4 0.242
Procedure Duration 55.5 ± 8.1 43.2 ± 6.2 0.217
BMI body mass index
Fig. 2 Individual response to ESWL according to the up-and-down sequence by using target-controlled infusion of remifentanil. When a patient
showed an increase in either heart rate or mean arterial pressure of 15 % or higher from the pre-ESWL value, the target concentration of remifentanil in
the next patient was increased (open symbols). Although neither heart rate nor mean arterial pressure increased by 15 % compared with the pre-ESWL
value, the concentration of remifentanil in the next patient was decreased (filled symbols). ESWL, extractoreal shock wave lithotripsy
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and might be regarded as the standard monitored
anesthesia care for ESWL of pancreatic stones.
Sedation and analgesia with remifentanil has been uti-
lized in anesthesia for urinary ESWL [9, 10]. However, the
EC50 of remifentanil in the Rem group of our study
(4.00 ng/ml) was higher than that in anesthesia (2.8 ng/ml)
for the ESWL of urinary stones [11]. Thus, the pain
induced by ESWL of pancreatic stones might be more se-
vere than that induced by ESWL of urinary stones. The
cardiopulmonary inhibition of remifentanil was the pri-
mary risk in our study, especially at a high target concen-
tration. Nevertheless, our results did not demonstrate
inhibition of circulation by remifentanil during ESWL,
even though the target concentration of remifentanil
reached 5.0 ng/ml in the two patient populations. Al-
though the respiratory rate was observed to be slower in
some patients, the lowest Ramsay sedation scale is 2, and
all patients could be roused to avoid respiratory inhibition.
Intraoperative body movement was another issue con-
cerned by the gastroenterological physicians.5 In this study,
we did not observe any body movement during the pro-
cedure and no mechanical adverse events were induced
while the procedure was conducted.
The addition of flurbiprofen axetil provided several
advantages for the remifentanil sedation. Firstly, it reduced
the remifentanil amount and prevented over-sedation and
respiratory depression, while demonstrating a higher
Ramsay sedation scale, higher lowest SpO2, as well as less
frequency of intraoperative wake-up. Secondly, it im-
proved the inhibition of sympathetic responses that were
induced by the ESWL procedures due to a decreased
MAP and HR in the Rem+ Flu group, at the highest level
and after procedure. Less sympathetic responses should be
very helpful in patients with high risk of cardiovascular
Fig. 3 VAS score and Ramsay sedation scale in the two groups (n = 30 for both groups). *p = 0.032
Fig. 4 MAP and HR before induction, after induction, at the highest level and after procedure in the two groups (n = 30 for both groups). MAP,
mean arterial pressure; HR, heart rate. *p < 0.05
Yang et al. BMC Anesthesiology  (2015) 15:161 Page 5 of 7
diseases. Thirdly, flurbiprofen axetil also decreased the in-
cidence of PONV, which was induced by remifentanil
administration.
PONV is the most common adverse effect of general
anesthesia, which is known to possess an incidence rate
that is higher than 30 % [18]. In our study, the incidence
of PONV was recorded to be 46.7 % in the Rem group
and remained as high as 26.7 % in Rem + Flu group, des-
pite a reduction in the concentration of remifentanil. The
high incidence of PONV might warrant the use of prophy-
lactic anti-emetic medications, which should be investi-
gated in future trials. Any severe complication induced by
postoperative nausea and vomiting, such as: hemorrhage,
perforation, or pancreatitis, was not observed.
The main limitation of our study was that it did not com-
pare the sedation strategy with conventional anesthesia,
such as general anesthesia or epidural anesthesia. However,
we are convinced that the simplified and safe manipula-
tion, as well as the shortened induction and recovery
time, would be a more preferable option for patients,
anesthesiologist, and gastroenterological physicians.
Conclusions
In summary, our study demonstrated that monitored
anesthesia care with remifentanil provided satisfied
sedation and analgesia for ESWL of pancreatic stones.
The EC50 of remifentanil was 4.0 ng/ml (3.84 ng/ml,
4.16 ng/ml) and 2.76 ng/ml (2.63 ng/ml, 2.89 ng/ml) in
the presence or absence of flurbiprofen axetil respect-
ively. The use of flurbiprofen axetil decreased the inci-
dence of respiratory depression and PONV induced by
remifentanil, while preventing sympathetic responses
that were induced by the procedure, in a more effective
fashion. The prophylactic use of anti-emetic medica-
tions should be further evaluated in another random-
ized controlled trial.
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